Tealwood Asset Management Inc. trimmed its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 2.4% in the third quarter, Holdings Channel reports. The fund owned 62,063 shares of the biotechnology company’s stock after selling 1,548 shares during the period. Tealwood Asset Management Inc.’s holdings in Exelixis were worth $1,356,000 as of its […]
- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 -
- Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the.
Exelixis, Inc. today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones..
Financial Comparison: Citius Pharmaceuticals (NASDAQ:CTXR) & Takeda Pharmaceutical (NYSE:TAK) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.